<DOC>
	<DOCNO>NCT01648634</DOCNO>
	<brief_summary>The objective determine whether nebivolol , beta-blockade drug , prevent development heart disease patient Duchenne muscular dystrophy age 10 15 year-old .</brief_summary>
	<brief_title>Nebivolol Prevention Left Ventricular Systolic Dysfunction Patients With Duchenne Muscular Dystrophy</brief_title>
	<detailed_description>A 1.25 mg-test dose administrate assess treatment tolerance randomization . A forced titration nebivolol placebo perform 2 week period . Full dose nebivolol placebo 5mg/day ( 7.5mg/day patient whose weight &gt; 60kg ) .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<mesh_term>Nebivolol</mesh_term>
	<criteria>Duchenne muscular dystrophy genetically proven Age 10 15 year Left ventricular ejection fraction assess radionuclide angiography ≥50 % measure within 3 month Systolic blood pressure ≥80 mmHg Diastolic blood pressure ≥70 mmHg Heart rate &lt; 50 bpm 2nd 3rd degree atrioventricular block , sinus node dysfunction Asthma bronchospasm Severe peripheral circulatory disease Hypersensitivity nebivolol excipients Metabolic acidosis Blood urea &gt; 7 mmol/l Liver transaminases enzymes &gt; 6 fold upper limit normal Formal indication betablockade treatment Cardiac treatment except angiotensinconverting enzyme inhibitor Participation another clinical trial within 3 month</criteria>
	<gender>Male</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Nebivolol</keyword>
	<keyword>beta-blockade treatment</keyword>
</DOC>